News Search Results
Apr 29, 2026, 07:47 ET AbbVie Reports First-Quarter 2026 Financial Results
UP-AA clinical program in which Rinvoq achieved the primary endpoint as well as key secondary endpoints. At the 2026 American Academy of Dermatology (AAD) Annual Meeting, AbbVie presented key data reinforcing the company's leadership in advancing standards of care across immune-mediated
More news about: AbbVie
Apr 23, 2026, 08:43 ET Dr. Reju-All Debuts Pharmacist-Led Skincare Approach at AAD 2026, Engaging Nearly 5,000 Industry Professionals
K-pharmacy skincare brand rooted in ingredient-driven formulation, debuted its pharmacist-led approach at the American Academy of Dermatology (AAD) Annual Meeting 2026. Positioned at the intersection of pharmaceutical expertise and dermatology-inspired skincare, the
More news about: Dr. Reju-All
Apr 21, 2026, 15:21 ET /C O R R E C T I O N -- American Academy of Dermatology/
In the news release, American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines, Highlighting Prevention Strategies and Effective Treatments, issued 07-Apr-2026 by American Academy of Dermatology over PR Newswire, we are advised by the company that the 5th bullet in
More news about: American Academy of Dermatology
Apr 21, 2026, 10:10 ET THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
Symposium, "Championing Evidence-Based Dermatology and Collaboration," on March 26, 2026, in Denver, Colorado. Held in conjunction with the American Academy of Dermatology (AAD) Annual Meeting, this
More news about: Skin of Color Society
Apr 20, 2026, 07:30 ET 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
Rezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity-Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis. 2026 American Academy of Dermatology (AAD), Denver, ColoradoPrimary estimand analysis was used at time of week 36 database lock in mITT adapted population. Patients
More news about: Nektar Therapeutics
Apr 07, 2026, 13:24 ET Dwayne "The Rock" Johnson's Award-Winning PAPATUI Puts Daily Sunscreen On Every Guy's Radar
American Academy of DermatologyMedia [email protected]
More news about: PAPATUI
Apr 01, 2026, 09:00 ET Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
presented data from the multiple ascending dose (MAD) cohorts of the Phase 1 trial evaluating BBT001 in healthy volunteers at the 2026 American Academy of Dermatology Annual Meeting (AAD 2026) in Denver, Colorado. The AAD 2026 clinical poster of BBT001 titled, "Safety, Tolerability, Pharmacokinetics,
More news about: Bambusa Therapeutics, Inc.
Mar 30, 2026, 08:00 ET Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
March 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in our aesthetics portfolio and insights on the aesthetic
More news about: AbbVie
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
with at least one additional weight-related comorbid condition. These results were presented in a late-breaking presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting and simultaneously published in Arthritis & Rheumatology. At the primary endpoint of 36 weeks, treatment
More news about: Eli Lilly and Company
Mar 28, 2026, 12:36 ET Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
March 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.
More news about: Nektar Therapeutics
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
More news about: Johnson & Johnson
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will present 14 abstracts during the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 27-31, 2026 in Denver, Colorado. The breadth of data reinforces the company's expertise across dermatology
More news about: Sun Pharma
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado. AbbVie will present 24 abstracts at AAD, including one late-breaking presentation,
More news about: AbbVie
Mar 27, 2026, 09:05 ET Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31 in Denver, demonstrating that its DecisionDx-Melanoma test refines mortality risk within
More news about: Castle Biosciences, Inc.
Mar 27, 2026, 09:03 ET OLAY Unveils Proprietary Research on Cell Adhesion as a Key Driver of Skin Aging at AAD 2026
OLAY, the #1 anti-aging skin care brand with more than 70 years of skin science expertise, is announcing new research at the 2026 American Academy of Dermatology (AAD) Annual Meeting, identifying cell adhesion as a critical biological driver of visible skin aging. These findings provide new insight
More news about: OLAY
Mar 27, 2026, 09:00 ET Murad Alam, MD, MSCI, MBA, FAAD, assumes presidency of the American Academy of Dermatology
/PRNewswire/ -- Chicago-based board-certified dermatologist Murad Alam, MD, MSCI, MBA, FAAD, will begin his one-year term as president of the American Academy of Dermatology at the close of the AAD's Annual Meeting.
More news about: American Academy of Dermatology
Mar 27, 2026, 09:00 ET American Academy of Dermatology Installs New Officers, Board Members
2026 /PRNewswire/ -- Two new officers and four new board members will be installed upon the conclusion of the 2026 Annual Meeting of the American Academy of Dermatology. The officers and board members are all board-certified dermatologists and members of the AAD, the world's largest dermatologic society
More news about: American Academy of Dermatology
Mar 27, 2026, 09:00 ET The future of skin aging may be found in the kitchen: 2026 American Academy of Dermatology Annual Meeting to highlight latest advancements in skin, hair, and nails
Emerging research on the role of nutrition in skin aging is one of the timely and impactful topics that will be discussed at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27-31 in Denver, Colorado.
More news about: American Academy of Dermatology
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1 "These data underscore our unwavering commitment to expanding
More news about: Eli Lilly and Company
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31. These data assess BIMZELX® (bimekizumab-bkzx) in providing on-treatment remission,
More news about: UCB
Mar 27, 2026, 09:00 ET UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
global biopharmaceutical company, today announced data for BIMZELX in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, on March 27–31. These data from three post hoc analyses of the BE HEARD trials show the potential of BIMZELX
More news about: UCB
Mar 27, 2026, 06:45 ET Neutrogena®, Aveeno® and Rogaine® Release New Dermatology Research and Clinical Skincare Innovations on Healthy Aging, Moisturization, Sun Protection and Acne
scientific advances in UV absorption technologies, lasting hydration, barrier supporting ingredients, and preferred acne solutions at the 2026 American Academy of Dermatology Annual Meeting (AAD 2026)SUMMIT, N.J., March 27, 2026
More news about: Kenvue Inc.
Mar 26, 2026, 08:27 ET DermTech 2.0 Further Expands DermTech Stratum with Clinical Trial Support Services
www.dermtechstratum.com or talk to the DermTech Stratum team at the upcoming American Academy of Dermatology meeting in Denver, CO.
More news about: DermTech LLC
Mar 25, 2026, 09:02 ET Revance Presents Award-Winning Aesthetics and Skincare Portfolio at 2026 AAD Annual Meeting
regenerative and consumer skincare company, will showcase the latest innovations and new indications across its extensive portfolio at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31, 2026, in Denver, Colorado. The company will host a series of in-booth educational sessions
More news about: Revance
Mar 25, 2026, 06:03 ET New Clinical Frontiers for Acclaro's UltraClear® 2910 nm Fiber Laser Revealed by Leading Experts at the American Academy of Dermatology Annual Meeting
Fiber Focus Sessions" at the American Academy of Dermatology annual meeting on March 26-31, 2026, taking place in Denver, CO.
More news about: Acclaro Corporation